Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyWellfleet E/I/U Coverage Policy Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedWellfleetPolicy UR-015

    Experimental, Investigational, and Unproven Services Utilization Review Guideline

    Customize your policy alerts

    Sign up for wellfleet Policy UR-015 alerts

    Get alerted when Policy UR-015 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs Wellfleet utilization review for Experimental/Investigational/Unproven (E/I/U) services billed under applicable CPT/HCPCS codes for providers and facilities billing under Student Health Insurance Plans insured by Wellfleet Insurance Company that include utilization review.

    Policy Summary
    PayerWellfleet
    PolicyExperimental, Investigational, and Unproven Services Utilization Review Guideline
    Policy CodePolicy UR-015
    Change TypeModified
    Effective DateAugust 1, 2026
    Next Review DateJune 1, 2027
    Key ActionReview requests involving listed experimental, investigational, or unproven services because they may be denied or treated as noncovered.
    SourceLink
    POLICY UPDATE CHANGES

    The document was changed from a Wellfleet Payment Guideline to a Utilization Review Guideline.

    The Experimental/Investigational/Unproven code list was updated for 2026.

    All SHIP plansApplicable plans
    Not coveredE/I/U services
    2026Code-list year
    URAC-certified IROExternal review organization
    4Classification criteria

    Experimental, Investigational, and Unproven Coverage Criteria

    E/I/U Classification

    A service is considered experimental, investigational, or unproven when ANY ONE of the following conditions is met:

    ANY of the following

    • The service does not have unrestricted market approval from the FDA or final approval from another governmental regulatory body.
    • There is insufficient or inconclusive medical and scientific evidence to evaluate the service's therapeutic value.
    • The service is not medically necessary, and a safe and medically accepted alternative is available.
    • The service is a medical device established by the FDA as Category A.

      Generally not covered because safety and effectiveness have not yet been established.

    Policy Summary
    PayerWellfleet
    PolicyExperimental, Investigational, and Unproven Services Utilization Review Guideline
    Policy CodePolicy UR-015
    Change TypeModified
    Effective DateAugust 1, 2026
    Next Review DateJune 1, 2027
    Key ActionReview requests involving listed experimental, investigational, or unproven services because they may be denied or treated as noncovered.
    SourceLink
    On This Page
    Experimental, Investigational, and Unproven Coverage CriteriaExperimental, Investigational, and Unproven Code ListsUtilization Review and Denial ConsiderationsGuideline BackgroundKey Definitions

    General Coverage Standard

    Coverage is limited to services and supplies meeting ALL of the following requirements:

    ALL of the following

    • The service or supply is proven safe.
    • The service or supply is proven efficacious.
    • The service or supply is comparable or superior to conventional services or supplies.

    Experimental, Investigational, or Unproven Services

    The following requested services and procedures are identified under this utilization review guideline as experimental, investigational, or unproven:

    The requested service or procedure is identified by this guideline as experimental, investigational, or unproven.

    Services and procedures listed under this guideline may be denied as not covered.

    Experimental, Investigational, or Unproven Services

    The following services and procedures are classified under the Experimental/Investigational/Unproven Utilization Review Guideline:

    The requested service or procedure appears in the services and procedures listed in this guideline as experimental, investigational, or unproven.

    The listed items are subject to the applicable utilization-review determination.

    Experimental, Investigational, or Unproven Services

    The following types of items are classified as experimental, investigational, or unproven when they appear in the guideline's code list:

    The requested service, procedure, test, device, product, or technology appears in the guideline's experimental/investigational/unproven code list.

    Coverage outcome may depend on the member benefit and applicable utilization review policy.

    Experimental, Investigational, or Unproven Services

    The following services and products are designated as experimental, investigational, or unproven when identified in the guideline's code list:

    The requested service, procedure, product, device, laboratory test, or treatment is identified in the guideline's code list as experimental, investigational, or unproven.

    The listed items include services, procedures, genetic tests, devices, biologic grafts, wound matrices, amniotic products, and clinical-trial services.

    Any service or supply that falls within Wellfleet’s definition of experimental, investigational, or unproven (E/I/U) is not a covered benefit. Covered services and supplies must be proven safe, efficacious, and comparable or superior to conventional alternatives.

    Services, products, devices, procedures, laboratory tests, and clinical-trial services listed in the guideline are identified as E/I/U and are excluded from standard covered utilization. This includes the listed CPT, HCPCS, and S-code items, including services provided as part of a Phase I clinical trial.

    A service is classified as E/I/U when it is not medically necessary and a safe, medically accepted alternative is available. This is one of the criteria Wellfleet uses to determine that a service is experimental, investigational, or unproven.

    Services and tests identified in the guideline as experimental, investigational, or unproven are subject to noncoverage or denial under the applicable utilization-review determination.

    Experimental, Investigational, and Unproven Code Lists

    Experimental/Investigational/Unproven Code List for 2026CPTExperimental
    64629Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral.
    81225CYP2C19 gene analysis, common variants.
    81229Cytogenomic genome-wide analysis for constitutional chromosomal abnormalities; copy number and SNP variants, comparative genomic.
    81230CYP3A4 gene analysis, common variants.
    81231CYP3A5 gene analysis, common variants.
    81265Comparative analysis using Short Tandem Repeat markers; patient and comparative specimen.
    81266Comparative analysis using Short Tandem Repeat markers; each additional specimen.
    81283IFNL3 gene analysis, rs12979860 variant.
    81291MTHFR gene analysis, common variants.
    81346TYMS gene analysis, common variants.
    1–10 of 33
    1/4
    Experimental, investigational, or unproven servicesCPTExperimental
    81504Oncology tissue of origin, microarray gene expression profiling of more than 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores.
    81524Oncology central nervous system tumor, DNA methylation analysis of at least 10,000 methylation sites, algorithm reported as probability of matching a reference tumor family and class.
    82397Chemiluminescent assay immunoassay for analyte other than infectious agent antibody or antigen.
    83520Immunoassay for analyte other than infectious agent antibody or antigen; quantitative, not otherwise specified.
    84112Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral.
    85415Fibrinolytic factors and inhibitors; plasminogen activator.
    86152Cell enumeration using immunologic selection and identification in fluid specimen.
    86153Cell enumeration using immunologic selection and identification in fluid specimen; physician interpretation and report, when required.
    87481Infectious agent detection by nucleic acid, not otherwise specified; amplified probe technique, each organism.
    87798Digitization of glass microscope slides for in situ hybridization, per specimen.
    1–10 of 57
    1/6
    Experimental, Investigational, or Unproven CodesCPTExperimental
    0299UOncology pan tumor, whole genome optical genome mapping of paired malignant and normal DNA specimens, comparative structural variant identification.
    0300UOncology pan tumor, whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, comparative sequence analyses and variant identification.
    0306UAnalysis, cell-free DNA, initial baseline assessment to determine patient-specific panel.
    0307UOncology minimal residual disease, next-generation targeted sequencing analysis of patient-specific panel, subsequent assessment to evaluate MRD.
    0312UImaging and placement of bone graft(s) or synthetic device(s), single cervical level.
    0313UOncology pancreas, DNA and mRNA next-generation sequencing analysis of 74 genes and CEA expression, pancreatic cyst fluid, categorical result.
    0314UAnalysis of 35 genes, categorical result.
    0315UProfiling by RT-PCR of 40 genes, categorical risk result.
    0317UAlgorithm-generated risk evaluation; nephrology renal transplant, RNA expression by select transcriptome.
    0319USequencing using pretransplant peripheral blood, risk score for early acute rejection; nephrology renal transplant, RNA expression by select transcriptome.
    1–10 of 67
    1/7
    Experimental, Investigational, or Unproven CodesCPTExperimental
    0489TOptical coherence tomography of middle ear, with interpretation and report; bilateral.
    0489UAutologous adipose-derived regenerative cell therapy for scleroderma in the hands, including tissue harvesting, isolation, preparation, and determination of regenerative cell concentration.
    0490TObstetrics single-gene noninvasive prenatal test, cell-free DNA sequence analysis to identify inherited pathogenic variants and fetal risk score.
    0494TAutologous adipose-derived regenerative cell therapy for scleroderma in the hands; multiple injections in one or both hands.
    0495TSurgical preparation and cannulation of marginal cadaver donor lung(s) to ex vivo organ perfusion system, including cold preservation prior to implantation.
    0495ULikelihood of clinically significant prostate cancer based on clinical information and algorithmic analysis.
    0496TInitiation and monitoring of marginal cadaver donor lung organ perfusion system by physician or qualified health care professional; first two hours in sterile field.
    0496UOncology colorectal, cell-free DNA, genes for mutations and methylation, and protein markers by assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk.
    0497UOncology prostate, mRNA gene-expression profiling by real-time RT-PCR of 6 genes, formalin-fixed paraffin-embedded tissue, algorithm reported as prostate cancer risk score.
    Experimental, Investigational, or Unproven CodesCPTExperimental
    0510UOncology pancreatic cancer, augmentative algorithmic analysis of genes from previously sequenced RNA whole-transcriptome data, reported as predicted molecular subtype probability.
    0511TElectroretinography with interpretation and report, pattern ERG.
    0516UDrug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status.
    0525TRemoval and reinsertion of sinus tarsi implant.
    0526TInsertion or replacement of intracardiac ischemia monitoring system; complete system including electrode and implantable monitor.
    0527TInsertion or replacement of intracardiac ischemia monitoring system; electrode only.
    0528TInsertion or replacement of intracardiac ischemia monitoring system; implantable monitor only.
    0529TProgramming device evaluation of intracardiac ischemia monitoring system with iterative adjustment, analysis, review, and report.
    0541TInterrogation device evaluation of intracardiac ischemia monitoring system with analysis, review, and report.
    0546TMyocardial imaging by magnetocardiography for detection of cardiac ischemia; interpretation and report.
    1–10 of 12
    1/2
    Experimental, Investigational, or Unproven CodesCPTExperimental
    0558TBone strength and fracture risk using finite element analysis and bone mineral density from CT data; interpretation and report.
    0559TComputed tomography scan taken for purpose of biomechanical computed tomography analysis.
    0560TAnatomic model 3D-printed from image data set(s); first individually prepared and processed component.
    0561TAnatomic model 3D-printed from image data set(s); each additional component.
    0562TAnatomic guide 3D-printed and designed from image data set(s); first anatomic guide.
    0563TAnatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide.
    0613UOncology urothelial carcinoma, DNA methylation and mutation analysis of biomarkers by methylation-specific PCR and targeted next-generation sequencing, urine, algorithm reported as probability index.
    0615TRemote monitoring of external continuous pulmonary fluid monitoring system; analysis of data received and transmission of reports to physician or qualified health care professional.
    0620TAutomated eye-movement analysis of binocular eye movements without spatial calibration, including disconjugacy, saccades, and pupillary dynamics for assessment of concussion, with interpretation and report.
    Experimental, Investigational, or Unproven CodesCPTExperimental
    0630UOncology breast, mRNA gene expression profiling by microarray, formalin-fixed paraffin-embedded tissue, algorithm reported as diagnostic molecular subtype index.
    0631TEndovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s), closure, vascular access, imaging guidance, and radiological supervision and interpretation.
    0635UAI Alzheimer disease mRNA next-generation sequencing gene expression profiling, 487 genes, non-invasive.
    0641TNoncontact near-infrared spectroscopy studies of flap or wound; image acquisition, interpretation and report, each flap or wound.
    Experimental, Investigational, or Unproven CPT Category III CodesCPTExperimental
    0724TQuantitative magnetic resonance cholangiopancreatography including data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of same anatomy during same session.
    0748TInsertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance and patch graft when performed.
    0753TAblation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance.
    0760TDigitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure.
    0762TDigitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure.
    0763TDigitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry, quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual.
    0764TInjections of stem cell product into perianal perifistular soft tissue, including fistula preparation.
    0765TAssistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction related to concurrently performed electrocardiogram.
    0782TGastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report.
    0791TBronchoscopy with insertion of esophageal protection device and circumferential radiofrequency destruction of pulmonary nerves; unilateral mainstem bronchus.
    1–10 of 27
    1/3
    Experimental/Unproven CPT Category III CodesCPTExperimental
    0890TCare delivery involving inhaled anesthetic agents and oxygen to assist anesthesia.
    Experimental/Unproven CPT Category III CodesCPTExperimental
    0909TEach additional application of concurrent optical and magnetic stimulation therapy, total wound surface area less than or equal to 50 sq cm.
    0910TReplacement of integrated neurostimulation system, vagus nerve.
    0911TRemoval of integrated neurostimulation system, vagus nerve.
    0912TElectronic analysis of implanted integrated neurostimulation system, vagus nerve, without programming by physician or qualified health care professional.
    0913TElectronic analysis of implanted integrated neurostimulation system, vagus nerve.
    Experimental/Unproven CPT Category III CodesCPTExperimental
    0914TDiagnostic coronary angiography performed at a separate session from an interventional procedure is separately reportable.
    0915TPercutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon performed on a separate target lesion from treated target lesion, including imaging supervision, interpretation, and report.
    0916TInsertion of permanent cardiac contractility modulation-defibrillation system components, including fluoroscopic guidance and evaluation/programming; pulse generator and dual transvenous electrodes/leads.
    0917TInsertion of permanent cardiac contractility modulation-defibrillation system component; pulse generator only.
    0918TInsertion of permanent cardiac contractility modulation-defibrillation system component; single transvenous lead only.
    0919TInsertion of permanent cardiac contractility modulation-defibrillation system component; dual transvenous leads only.
    0920TRemoval of permanent cardiac contractility modulation-defibrillation system component; pulse generator only.
    0921TRemoval of permanent cardiac contractility modulation-defibrillation system component; single transvenous pacing lead only.
    0922TRemoval of permanent cardiac contractility modulation-defibrillation system component; single transvenous defibrillation lead only.
    0923TRemoval of permanent cardiac contractility modulation-defibrillation system component; dual pacing and defibrillation transvenous leads only.
    Experimental/Unproven CPT Category III CodesCPTExperimental
    0931TElectrophysiologic evaluation of cardiac contractility modulation-defibrillator lead including defibrillation-threshold evaluation, at time of initial implantation or replacement with testing of pulse generator.
    0940TExternal electrocardiographic recording for greater than 15 days up to 30 days; scanning analysis with report.
    0942TCystourethroscopy, flexible, with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization.
    0943TCystourethroscopy, flexible, with removal and replacement of prostatic urethral scaffold.
    Experimental/Unproven CPT Category III CodesCPTExperimental
    0944TCystourethroscopy, flexible, with removal of prostatic urethral scaffold.
    0945T3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation.
    0946TIntraoperative assessment for abnormal tissue following partial mastectomy using computer-aided fluorescence imaging.
    0948TInterrogation device evaluation, remote, up to 90 days, cardiac contractility modulation system with interim analysis, review, and reports by physician or qualified health care professional.
    0949TInterrogation device evaluation, remote, up to 90 days, cardiac contractility modulation system, remote data acquisition, receipt of transmissions, technician review, technical support, and distribution of results.
    Experimental/Unproven CPT Category III CodesCPTExperimental
    0952TTotally implantable active middle ear hearing implant; revision or replacement, with mastoidectomy and replacement of sound processor.
    0953TTotally implantable active middle ear hearing implant; revision or replacement, without mastoidectomy and replacement of sound processor.
    0954TTotally implantable active middle ear hearing implant; replacement of sound processor only, with attachment to existing transducers.
    0955TTotally implantable active middle ear hearing implant; removal, including removal of sound processor and all implant components.
    0969TRemoval of epicranial neurostimulator system.
    0970TAblation, benign breast tumor, percutaneous, laser, including imaging guidance when performed, each tumor.
    Experimental/Unproven CPT Category III CodesCPTExperimental
    0971TAblation, malignant breast tumor(s), percutaneous, laser, including imaging guidance when performed, unilateral.
    0973TSelective enzymatic debridement of partial-thickness and/or full-thickness burn eschar requiring anesthesia, including patient monitoring, trunk, arms.
    Experimental, investigational, or unproven services and productsmixedExperimental
    0949TInterrogation device evaluation, remote, up to 90 days, cardiac contractility modulation system, remote data acquisition, receipt of transmissions, technician review, technical support, and distribution of results.
    0952TTotally implantable active middle ear hearing implant; revision or replacement, with mastoidectomy and replacement of sound processor.
    0953TTotally implantable active middle ear hearing implant; revision or replacement, without mastoidectomy and replacement of sound processor.
    0954TTotally implantable active middle ear hearing implant; replacement of sound processor only, with attachment to existing transducers.
    0955TTotally implantable active middle ear hearing implant; removal, including removal of sound processor and all implant components.
    0969TRemoval of epicranial neurostimulator system.
    0970TAblation, benign breast tumor, percutaneous, laser, including imaging guidance when performed, each tumor.
    0971TAblation, malignant breast tumor(s), percutaneous, laser, including imaging guidance when performed, unilateral.
    0973TSelective enzymatic debridement of partial-thickness and/or full-thickness burn eschar requiring anesthesia, including patient monitoring, trunk, arms, legs; first 100 sq cm.
    0974TSelective enzymatic debridement of partial-thickness and/or full-thickness burn eschar requiring anesthesia, including patient monitoring, trunk, arms, legs; each additional 100 sq cm.
    1–10 of 57
    1/6
    Experimental or unproven CPT Category III and molecular testing codesCPTExperimental
    1047TEach additional 50 sq cm, or each additional 0.5% of body area of infants and children, or part thereof, for autologous heterogeneous skin-construct graft application.
    1048TAutologous heterogeneous skin-construct graft application, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 50 sq cm or less.
    1049TAutologous heterogeneous skin-construct graft application, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 50 sq cm or each additional 0.5% of body area.
    1051TRemoval of subcutaneous heart failure decompensation monitor; interrogation device evaluation, in person or remote, up to 30 days, insertable.
    1052TSubcutaneous heart failure decompensation monitor, with physiologic parameter analysis, report generation, review, and interpretation.
    1053THeart failure decompensation monitor, with physiologic parameter analysis, report generation, review, and interpretation.
    81529Oncology cutaneous melanoma, mRNA gene expression profiling by real-time RT-PCR of 31 genes, formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk including sentinel lymph node metastasis likelihood.
    81535Oncology gynecologic, live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as drug response score; first single drug or drug combination.
    81536Oncology gynecologic, live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as drug response score; each additional single drug or drug combination.
    81540Oncology tumor of unknown origin, mRNA gene expression profiling by real-time RT-PCR of 92 genes to classify tumor into main cancer type and subtype, algorithm reported as probability of predicted cancer type and subtype.
    Experimental or unproven biologic and graft HCPCS codesHCPCSExperimental
    A2004SurgiMend; XCelliStem, 1 mg.
    A2021Membrane Wrap Flow; NeoMatriX, per sq cm.
    A2033Matrix HD; Myriad Morcells, 4 mg.
    A2039Fortaderm/PuraPly; PuraPly Wound Matrix; InnovaMatrix FD, per sq cm.
    C1763Amniorepair/Altiply; Esano AAA.
    Experimental or unproven device, procedure, and biologic product codesHCPCSExperimental
    C8002Axolotl Graft; Polygon3 Membrane.
    C9352Axolotl Graft; NeoStim TL.
    C9353Axolotl Graft; NeoThelium FT.
    C9358Axolotl Graft; SurGraft ACA.
    C9360Axolotl Graft; XWrap.
    C9364Axolotl Graft; Oasis Burn Matrix.
    C9399Axolotl Graft; AC5 Advanced Wound System.
    G0455Orthopedic implant movement analysis using paired computed tomography examination of target structure, including data acquisition, preparation, transmission, interpretation, and report.
    G9143Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen.
    J3590AmnioBand Particulate.
    1–10 of 18
    1/2
    Experimental or unproven biologic graft and surgical product codesHCPCSExperimental
    Q4130Restorigin Amniotic Fluid; Strattice, per sq cm.
    Q4133Revita.
    Q4137Amnio Burgeon Membrane and Hydromembrane; AmnioExcel, AmnioExcel Plus or BioDExcel, per sq cm.
    Q4138Axolotl DualGraft; BioDFence DryFlex, per sq cm.
    Q4139AmnioClear LTC flowable; Amniocyte Flowable Matrix; Amniofix Injectable; Arthrex Amnion Viscous; Pro3 Amniotic Fluid; Renuva Allograft Adipose Matrix; AmnioMatrix or BioDMatrix, injectable, 1 cc.
    Q4140AmnioMatrix or BioDMatrix, injectable, 1 cc.
    Q4148Biodesign, DuraSorb, GORE BIO-A, OrthADAPT, OviTex, Phasix, SportMesh, TissueMend, Tornier BioFiber, Tutopatch, Viaflow, XenMatrix, XenoSure, Gentrix and related surgical graft products.
    Q4150Multiple amniotic, dermal, pericardial, wound, surgical mesh, barrier membrane, and biologic graft products including Actishield and AmnioCare.
    Experimental or unproven wound, nerve, and biologic graft productsHCPCSExperimental
    Q4152Cygnus; DermaPure, per sq cm.
    Q4155BioLab Tri-Membrane Wrap Flow; Neox Flo or Clarix Flo, 1 mg.
    Q4156BioDfence DryFlex; Neox 100 or Clarix 100, per sq cm.
    Q4159A/C Wrap; Affinity, per sq cm.
    Q4160NeuraGen Nerve Guide; NuShield, per sq cm.
    Q4162SurGraft TL; WoundEx Flow, BioSkin Flow, 0.5 cc.
    Q4163SurGraft FT; WoundEx, BioSkin, per sq cm.
    Q4164Esano ACA; Helicoll, per sq cm.
    Q4166Coretext and Protext; Cytal, per sq cm.
    Q4168Allopatch HD; Amnioband, 1 mg.
    1–10 of 21
    1/3
    Experimental or unproven biologic graft, wound matrix, tissue displacement, and device codesHCPCSExperimental
    Q4205InnovaMatrix FD; Membrane Graft or Membrane Wrap, per sq cm.
    Q4215Apollo FT; Axolotl Ambient or Axolotl Cryo, 0.1 mg.
    Q4222PalinGen Membrane, PalinGen HydroMembrane, PalinGen Xplus, PalinGen Xplus HydroMembrane; ProgenaMatrix, per sq cm.
    Q4229Clarix Cord 1K; Neox 1K; Neox RT; Cogenex Amniotic Membrane, per sq cm.
    Q4234SurGraft XT; XCellerate, per sq cm.
    Q4235AmnioExCel/AmnioExcel Plus/BioDExCel; AMNIOREPAIR or AltiPly, per sq cm.
    Q4236BioDfence; carePATCH, per sq cm.
    Q4246Amnio Burgeon XPlus Membrane and XPlus Hydromembrane; Amnio-Maxx or Amnio-Maxx Lite, per sq cm.
    Q4250Coll-e-Derm; Coretext or Protext, per cc.
    Q4253XCelliStem Wound Powder; Zenith Amniotic Membrane, per sq cm.
    1–10 of 62
    1/7
    Experimental or unproven special service codesHCPCSExperimental
    S3854Gene expression profiling panel for use in the management of breast cancer.
    S9988Treatment Reguard, for topical use only, per square centimeter.
    S9990Services provided as part of a Phase I clinical trial.
    Experimental/Unproven HCPCS CodesHCPCSExperimental
    Q4423Axolotl Graft Ultra
    Q4424Renati AC Membrane
    Q4428CuraMatrix
    Q4436Pretect
    Q4437RECELL Autologous Cell Harvesting Device
    Q4438PalinGen Flow; ProMatrX
    Q4440Cogenex Amniotic Membrane
    S3854Gene expression profiling panel for use in the management of breast cancer
    S9988Treatment Reguard, for topical use only, per square centimeter
    S9990Services provided as part of a Phase I clinical trial
    Prostate volume: less than 50 mL
    Prostate volume thresholdLess than 50 mL
    Coding distinctionUse the less-than-50-mL prostate-volume distinction when the documented prostate volume is below 50 mL.
    Associated serviceTransperineal laser ablation of benign prostatic hyperplasia, including imaging guidance.
    Prostate volume: greater than or equal to 50 mL
    Prostate volume thresholdGreater than or equal to 50 mL
    Coding distinctionUse the greater-than-or-equal-to-50-mL prostate-volume distinction when the documented prostate volume is 50 mL or larger.
    Listed code0868T — Prostate volume greater than or equal to 50 mL.

    Utilization Review and Denial Considerations

    Denial Risk

    E/I/U Services May Be Denied or Noncovered

    Claims may be denied or treated as noncovered when Wellfleet determines that a service or supply is Experimental, Investigational, or Unproven (E/I/U). This includes services without unrestricted FDA market approval or final approval from another governmental regulatory body, as well as services lacking sufficient evidence, lacking medical necessity when a safe accepted alternative exists, or involving an FDA Category A device.

    • E/I/U services are not covered benefits under this guideline.
    • Wellfleet limits coverage to services and supplies proven safe, efficacious, and comparable or superior to conventional alternatives.
    Billing Rule

    Unlisted or Additional Codes Require Review

    The E/I/U code list is not exhaustive. An unlisted code, a code absent from the list, or a newly introduced service that has not yet been assigned a CPT or HCPCS code may still be E/I/U and may be referred for utilization review.

    • Review the Unlisted Codes Payment Guideline when billing an unlisted code.
    • Wellfleet may subject additional codes to E/I/U utilization review and determine the service is not covered.
    Denial Risk

    Listed Experimental or Unproven Procedures

    Requests billed for identified molecular, genomic, diagnostic, sensory-testing, and other listed procedures may receive an adverse utilization-review determination when Wellfleet classifies the service as experimental, investigational, or unproven.

    • Examples include oncology and other gene-expression or sequencing assays, quantitative sensory testing, automated audiometry, and related diagnostic technologies.
    • Do not assume that assignment of a CPT, HCPCS, Category T, or Category U code establishes coverage.
    Denial Risk

    Denial as Experimental, Investigational, or Unproven

    Applicable requests may be denied as experimental, investigational, or unproven, including requests involving advanced genetic testing, genomic analysis, tissue or tumor profiling, and other technologies identified in the guideline.

    • Review the applicable utilization-review guideline before submitting these services.
    • A listed code does not override Wellfleet's E/I/U coverage determination.
    Denial Risk

    Utilization Review May Result in Noncoverage

    Experimental or unproven services may be noncovered or denied through utilization review when the request involves listed diagnostic, therapeutic, monitoring, imaging, or laboratory services.

    • Coverage is not established solely because a service is clinically requested or has an assigned billing code.
    • Submit documentation supporting medical necessity and applicable evidence when utilization review is required.
    Denial Risk

    Classified Services May Be Not Covered

    Services and procedures classified as experimental, investigational, or unproven may be denied as not covered, including the listed technologies and procedures in the guideline's later code ranges.

    • This risk applies across procedure types and is not limited to one specialty or code family.
    • Verify coverage before performing or billing a service that may meet the E/I/U definition.
    Denial Risk

    Follow the Applicable Utilization-Review Guideline

    A request may be denied under the applicable utilization-review guideline when Wellfleet determines that the service is experimental, investigational, or unproven, including newer procedures and technologies identified in the guideline.

    • Examples include emerging surgical, imaging, anesthetic, and neuromodulation-related services.
    • Use the current Wellfleet guideline and code list when evaluating a request.
    Denial Risk

    Listed Items Carry Denial Risk

    Wellfleet may deny listed experimental or unproven services, procedures, technologies, laboratory tests, biologic products, and other items identified in the guideline.

    • Examples include burn and wound treatments, remote physiologic monitoring, optical imaging, tumor and genetic testing, skin constructs, grafts, and wound matrices.
    • The listed examples are subject to the guideline's E/I/U determination and are not guaranteed covered benefits.
    Denial Risk

    Experimental or Unproven Products and Services

    Experimental or unproven services may be denied, including genetic tests, devices, biologic grafts, wound matrices, amniotic products, gene-expression panels, and clinical-trial-related services.

    • Examples include SurgiMend, XCelliStem, NeoMatriX, PuraPly, amniotic and other graft or membrane products, gene-expression profiling, and Phase I clinical-trial services.
    • Confirm coverage and utilization-review requirements before furnishing or billing these items.

    Guideline Background

    Wellfleet defines experimental, investigational, or unproven (E/I/U) services as medical procedures, equipment, medications, and cosmetic procedures that are not medically necessary and are not covered. A service may be classified as E/I/U when it lacks unrestricted FDA or other governmental approval, lacks sufficient or conclusive medical and scientific evidence of therapeutic value, is not medically necessary when a safe and medically accepted alternative is available, or is an FDA Category A medical device whose safety and effectiveness have not yet been established.

    Key Definitions

    Experimental/Investigational/Unproven (E/I/U) services
    What it includesMedical procedures, equipment, medications, and cosmetic procedures that are not medically necessary and are not covered.
    How a service qualifiesA service is E/I/U if it lacks unrestricted FDA or other governmental approval, has insufficient or inconclusive medical and scientific evidence, or is not medically necessary when a safe and medically accepted alternative is available.
    Coverage implicationServices meeting the E/I/U definition are not covered.
    FDA Category A medical device
    DefinitionA medical device established by the FDA as Category A.
    General coverage statusGenerally not covered.
    ReasonThe device’s safety and effectiveness have not yet been established.
    Experimental/Investigational/Unproven
    DesignationA service, procedure, product, device, laboratory test, or treatment identified by the guideline as experimental, investigational, or unproven.
    Where identifiedThe designation applies to items appearing in the guideline’s experimental/investigational/unproven code list.
    Coverage implicationListed items are identified as excluded from standard covered utilization under this guideline.